Oncotarget

Research Papers:

Protein kinase C beta II suppresses colorectal cancer by regulating IGF-1 mediated cell survival

Catríona M. Dowling, James Phelan, Julia A. Callender, Mary Clare Cathcart, Brian Mehigan, Paul McCormick, Tara Dalton, John C. Coffey, Alexandra C. Newton, Jacintha O’Sullivan & Patrick A. Kiely _

PDF  |  HTML  |  Supplementary Files  |  Order a Reprint

Oncotarget. 2016; 7:20919-20933. https://doi.org/10.18632/oncotarget.8062

Metrics: PDF 673 views  |   HTML 1070 views  |   ?  


Abstract

Catríona M. Dowling1,2,3, James Phelan4, Julia A. Callender5, Mary Clare Cathcart4, Brian Mehigan6, Paul McCormick6, Tara Dalton3, John C. Coffey7, Alexandra C. Newton5, Jacintha O’Sullivan4, Patrick A. Kiely1,2,3

1Graduate Entry Medical School and Health Research Institute (HRI), University of Limerick, Limerick, Ireland

2Department of Life Sciences, and Materials and Surface Science Institute, University of Limerick, Limerick, Ireland

3Stokes Research Institute, University of Limerick, Limerick, Ireland

4Department of Surgery, Trinity College Dublin, Dublin, Ireland

5Department of Pharmacology, University of California at San Diego, La Jolla, CA, USA

6GEMS, St. James Hospital, Dublin, Ireland

74i Centre for Interventions in Infection, Inflammation and Immunity, Graduate Entry Medical School, University of Limerick, Limerick, Ireland

Correspondence to:

Patrick A. Kiely, e-mail: Patrick.Kiely@ul.ie

Keywords: protein kinase C, IGF-1, cell survival, tumour suppressor, colorectal cancer

Received: October 02, 2015     Accepted: January 31, 2016     Published: March 14, 2016

ABSTRACT

Despite extensive efforts, cancer therapies directed at the Protein Kinase C (PKC) family of serine/threonine kinases have failed in clinical trials. These therapies have been directed at inhibiting PKC and have, in some cases, worsened disease outcome. Here we examine colon cancer patients and show not only that PKC Beta II is a tumour suppressor, but patients with low levels of this isozyme have significantly decreased disease free survival. Specifically, analysis of gene expression levels of all PKC genes in matched normal and cancer tissue samples from colon cancer patients revealed a striking down-regulation of the gene coding PKC Beta in the cancer tissue (n = 21). Tissue microarray analysis revealed a dramatic down-regulation of PKC Beta II protein levels in both the epithelial and stromal diseased tissue (n = 166). Of clinical significance, low levels of the protein in the normal tissue of patients is associated with a low (10%) 10 year survival compared with a much higher (60%) survival in patients with relatively high levels of the protein. Consistent with PKC Beta II levels protecting against colon cancer, overexpression of PKC Beta II in colon cancer cell lines reveals that PKC Beta II reverses transformation in cell based assays. Further to this, activation of PKC Beta II results in a dramatic downregulation of IGF-I-induced AKT, indicating a role for PKCs in regulating IGF-1 mediated cell survival. Thus, PKC Beta II is a tumour suppressor in colon cancer and low levels serve as a predictor for poor survival outcome.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 8062